DMAC
DMAC
NASDAQ · Biotechnology

Diamedica Therapeutics Inc

$6.85
+0.00 (+0.00%)
As of Sep 20, 10:28 PM ET ·
Analyst Consensus
Strong Buy
11
Analysts
Moderate
Coverage
Buy 10 91%
Hold 1 9%
Sell 0 0%
Price Target
Analyst Price Target -39.3% upside
Low Target $2.49
Average Target $4.16
High Target $4.48
Current Price $6.85
Current
$6.85
Target
$4.16
$2.49 $4.16 avg $4.48
Scenario Analysis
Bear Case
$2.49
-63.6%
Low target
Base Case
$4.16
-39.3%
Avg target
Bull Case
$4.48
+-34.6%
High target
Risk/Reward
0.5x
Unfavorable
Price in Context
52-Week High
$10.42
-34.3% from high
52-Week Low
$5.25
+30.6% from low
Target vs 52W High
$4.16
-60.1% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -2.9%
AMGN
Amgen Inc
Hold 43 47% $190.87 -53.5%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +137.6%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -14.9%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -90.4%
MRNA
Moderna Inc
Hold 30 37% $149.45 -18.1%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -63.4%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -40.8%